The present invention relates to the field of hemophilia therapy. Claimed are an isolated, recombinant, partially B-domain deleted factor VIII (FVIII) variant, characterized by increased coagulation activity in comparison to known factor VIII products, and a method for producing the same. Also claimed are a pharmaceutical composition comprising said FVIII variant and a method for producing the same; a polynucleotide encoding said FVIII variant; an expression vector comprising said polynucleotide; a mammalian cell comprising sais expression vector. Claimed are methods of treating hemophilia A and acquired hemophilia and the corresponding use of the claimed FVIII variant.
展开▼
